 On Tuesday morning, drugmaker Eli Lilly Co. NYSE:LLY announced that it plans to purchase Prevail Therapeutics Inc. NASDAQ:PRVL, a gene therapy developer, in an all-cash deal that values the acquisition at 1.04 billion, or 22.50 per share, representing an 80 premium to Mondays closing price. 